PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs. The company's leading product candidate, D-PLEX100, is currently undergoing Phase III clinical trials. It is being evaluated for its efficacy in preventing surgical site infections (SSIs) following both sternal (bone) and abdominal (soft tissue) procedures. Established in 2008, PolyPid Ltd. is headquartered in Petah Tikva, Israel.
The current price of PYPD is $5.05 USD — it has decreased by -0.59% in the past 24 hours. Watch Polypid stock price performance more closely on the chart.
What is Polypid stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Polypid stocks are traded under the ticker PYPD.
Is Polypid stock price growing?▼
PYPD stock has risen by +10.5% compared to the previous week, the month change is a +3.7% rise, over the last year Polypid has showed a +44.7% increase.
What is Polypid market cap?▼
Today Polypid has the market capitalization of 96.83M
When is the next Polypid earnings date?▼
Polypid is going to release the next earnings report on August 12, 2026.
What were Polypid earnings last quarter?▼
PYPD earnings for the last quarter are -0.35 USD per share, whereas the estimation was -0.43 USD resulting in a +19.23% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Polypid revenue for the last year?▼
Polypid revenue for the last year amounts to 0 USD.
What is Polypid net income for the last year?▼
PYPD net income for the last year is -34.17M USD.
How many employees does Polypid have?▼
As of July 02, 2026, the company has 57 employees.
In which sector is Polypid located?▼
Polypid operates in the Health & Wellness sector.
When did Polypid complete a stock split?▼
The last stock split for Polypid was on September 21, 2023 with a ratio of 1:30.